KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cost of Revenue: 2017-2025

Historic Cost of Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $510.5 million.

  • Amneal Pharmaceuticals' Cost of Revenue rose 17.93% to $510.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 7.09%. This contributed to the annual value of $1.8 billion for FY2024, which is 12.74% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Cost of Revenue of $510.5 million as of Q3 2025, which was up 16.49% from $438.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Cost of Revenue's 5-year high stood at $510.5 million during Q3 2025, with a 5-year trough of $301.5 million in Q1 2021.
  • Its 3-year average for Cost of Revenue is $430.4 million, with a median of $432.9 million in 2024.
  • In the last 5 years, Amneal Pharmaceuticals' Cost of Revenue decreased by 6.78% in 2021 and then rose by 19.21% in 2024.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Cost of Revenue stood at $371.2 million in 2021, then increased by 6.25% to $394.4 million in 2022, then climbed by 8.31% to $427.2 million in 2023, then rose by 9.48% to $467.6 million in 2024, then climbed by 17.93% to $510.5 million in 2025.
  • Its Cost of Revenue was $510.5 million in Q3 2025, compared to $438.3 million in Q2 2025 and $439.5 million in Q1 2025.